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STUDIES ON SERUM COPPER
II. THE COPPER LEVELS IN RELATION TO CORTICOSTEROID ADMINISTRATIONt
GEORGE LIPKIN, M.D., FRANZ IIERRMANN, M.D. AND LEONA MANDOL, BA.
In the course of our assays of the copper level
in blood sera of psoriaties, changes in the levels
were noted which appeared to occur under the
influence of systemic treatment with cortico-
steroid compounds (1). These changes have been
subjected to further studies.
It is the purpose of this paper to report the
pertinent observations made thus far—and to
correlate the observations with a number of
clinical and experimental findings obtained by
previous investigators, which would conform
with such an influence of corticosteroids.
METHODS AND SUBJECTS
The serum copper levels were assayed by means
of the spectrophotometrie method of Peterson and
Bollier (1, 2). Analyses were performed shortly
prior to the institution of steroid treatment, and
were repeated thereafter at intervals of at least
one week.
A total of 25 subjects participated in the study.
These included 20 patients with psoriasis and 5
healthy volunteers. Of the 20 psoriatics, 15 were
white males, 21 to 68 years of age, and 5 were white
females, 13 to 38 years of age. Three of the
5 healthy volunteers were white males, 28 to 34
years old, while 2 healthy female volunteers were
42 and 49 years old.
All subjects received triameinolone except one
who was treated with methylprednisolone. Of the
20 psoriaties, 17 received triamcinolone orally,
and 3 were treated with intralesional triam-
einolone injections. Of the 5 persons without skin
disease, 4 took triamcinolone, and the fifth methyl-
prednisolone by mouth. The oral dosage of triam-
einolone ranged from 8 to 32 mgm and that of
methylprednisolone was 16 mg a day. The 3 pa-
tients injected intralesionally in this way received
from 10 to 30 mg of triameinolone aeetonide once
weekly for several weeks.
EESULTS
Some decline in the copper level was noted in
most of the subjects during the period of ap-
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proximately one to five weeks following initia-
tion of the steroid treatment. On the basis of the
data obtained it appears expedient to appraise
this decline by Comparing the levels found two
weeks after start of the steroid treatment with
those obtained prior to treatmentt. Unfortu-
nately, the assays were not repeated in all of the
25 subjects precisely two weeks after the start
of treatment. It was necessary therefore to utilize
the values found after one week in 4 individuals
and the values found after three weeks for the
remaining 2, as the basis for the Comparison.
In this way it was demonstrable that the serum
copper level had declined from pretreatment
values in 13 of 17 psoriatics who took steroids
orally.
Four of the five non-psoriatic subjects on oral
steroids and even all of the three psoriatic patients
who received intralesional steroid injections
showed some decline in serum copper. The drop
in all of the 25 treated subjects averaged 0.54
meg per ml.
This finding was in contrast to the relative
individual constancy of the serum copper con-
tents observed in 4 untreated healthy subj ects
and 3 untreated psoriatie subj eets where a mean
deviation from the first value by not more than
0.01 mcg/ml [in the direction of a decline] was
noted in samples collected at random intervals of
from one to four weeks. This stability of the
serum copper levels per person has been sub-
stantiated also by previous assays (3).
The extent of the fall in serum copper levels
observed after steroid administration did not
appear to show any dependence on the steroid
dosage employed, but considerable variations
were noted in the response of different individuals
to one and the same amount of steroid.
As examples typical of our results, the data
obtained in 2 of the subjects are presented in
Figures 1 and 2.
Whenever the serum copper level declined
t We are indebted to Mrs. Lee F. Herrera,
Institute of Medical Statistics, New York Uni-
versity Medical Center for suggesting the ap-
praisal of our data in the manner here presented.
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after institution of the steroid treatment, this
change began within 1 to 2 weeks after the
therapy was started, and usually reached its
maximum in 1 to 3 weeks. At about that time,
however, a "rebound" elevation of the copper
level usually occurred to values higher than those
obtained prior to treatment, until, after several
months, stabilization was reached again at about
the original level. The "swing" of the depressed
copper values toward elevation—and then back
to the original levels, occurred, regardless of
whether the steroid medication was maintained,
tapered off graduaJly, or stopped abruptly.
DISCUSSION
The trends observed appeared to be independ-
ent of the presence or absence of psoriasis, but
were most likely related to the steroid adminis-
tration. It is noted that a similar copper level
curve was obtained after the use of methyl-
prednisolone in 1 patient as was obtained in those
receiving triamcinolone. However, additional
controlled studies are required to confirm these
impressions.
The fact that the wave-shaped "down-up-back"
swing of the levels occurred in very similar
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lesional injection of triamcinolone.
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fashion, whether the steroid amounts were con-
siderable or minor [intralesional injectioni,
whether the administration was of long or short
duration, etc., suggests a consistent occurrence
of a depleting effect of any corticosteroid ad-
ministration on the serum copper which is soon
followed by some natural compensatory mecha-
nism tending to restore the original level.
A number of previous clinical and experimental
reports indicate the existence of an interrelation-
ship between endocrine functions and blood
copper levels; in particular, the adrenals, thyroid,
pituitary and gonads appear to take part in this
relationship.
In humans, serum copper levels were found to
be elevated in hyperthyroidism (4—7), in Addison's
disease (5, 6, 8), during the last trimester of
pregnancy (5), and following administration of
estrogens (9, 10). Low normal levels were ob-
served in hypothyroidism (7). Decreased levels
were observed in patients with acute leukemias
treated with ACTH, regardless of the therapeutic
response (5), and also in patients with rheumatic
fever and rheumatoid arthritis treated with
adrenocortical hormones (11).
El-Mofty et at. reported that in rats an increase
in blood copper was produced by psoralens,
provided that the pituitary gland was intact,
and that this increase could be augmented further
by adrenaleetomy, and could be blocked or
reversed by cortisone administration (12).
Hundley and Ing by adrenalectomy succeeded in
preventing completely the development of aehro-
motrichia otherwise occurring in black rats under
the influence of a copper deficient diet (13) ; once
the achromotrichia had developed, the same
authors partly or wholly reversed the change
upon adrenalectomy or hypophysectomy (13).
In acute balance experiments, Wiesel found
that single 30-minute I. V. infusions of 100 mg
of hydrocortisone or 50 mg of prednisolone into
normal humans produced a transient fall of
serum copper, with the maximum decline at
2—3 hours; this was accompanied by a marked
increase in urinary copper excretion (14). Evi-
dence was also presented of the ability of gluco-
genie cortieosteroids to chelate with copper in
vitro, and it was proposed that such a mechanism
could explain the effect of eorticosteroids on the
redistribution of copper in body tissues (14). In
our own study, the corticosteroid was adminis-
tered either orally or intracutaneously, never
intravenously, and in considerably smaller
amounts over a longer period of time; the decrease
in serum copper levels did not become evident
in most cases until after one week. If the serum
copper decreases were due solely to a chelating
effect of steroids, one should not expect to find a
rebound elevation of copper during continued
steroid administration.
From the evidence cited, it would appear that,
in general, blood copper tends to vary in the
same direction as thyroid function, but in an
opposite direction to adrenal function. In this
connection, it is interesting to note that thyroxine
is capable of eomplexing very strongly with
copper (15), so that increased circulating thyroid
hormone might directly contribute to an eleva-
tion of blood copper.
It would also appear possible that the hyper-
eupremia observed in association with various
febrile conditions and with many subacute and
chronic infections, might at least in part result
from either reactively increased thyroid function
and/or from some adrenoeortieal insufficiency
caused by excessive stress.
SUMMARY AND CONCLUSION
1. Serum copper levels were determined weekly
in 20 psoriatics and 5 non-psoriatics receiving
adrenal eortieosteroids orally or intralesionally.
A tendency toward temporary lowering of serum
copper was noted in 20 of 25 subjects.
2. The tendency toward lowering of serum
copper appears to be a steroid effect, and not
peculiar to psoriasis.
3. Previous clinical and experimental evidence
was reviewed, which suggests the existence of an
interrelationship between serum copper and
several endocrine glands, especially adrenals.
thyroid, and pituitary.
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